Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 13 04:00PM ET
21.81
Dollar change
-0.71
Percentage change
-3.15
%
IndexRUT P/E- EPS (ttm)-2.82 Insider Own41.35% Shs Outstand25.64M Perf Week-15.89%
Market Cap559.26M Forward P/E- EPS next Y-3.52 Insider Trans0.07% Shs Float15.04M Perf Month-16.95%
Income-63.88M PEG- EPS next Q-0.85 Inst Own64.80% Short Float10.87% Perf Quarter8.40%
Sales0.00M P/S- EPS this Y67.11% Inst Trans-11.38% Short Ratio6.98 Perf Half Y28.60%
Book/sh12.52 P/B1.74 EPS next Y-20.69% ROA-26.64% Short Interest1.63M Perf Year17.57%
Cash/sh10.99 P/C1.98 EPS next 5Y- ROE-27.54% 52W Range12.12 - 48.31 Perf YTD-16.69%
Dividend Est.- P/FCF- EPS past 5Y-19.23% ROI-19.89% 52W High-54.85% Beta2.35
Dividend TTM- Quick Ratio40.33 Sales past 5Y0.00% Gross Margin- 52W Low79.95% ATR (14)1.81
Dividend Ex-DateOct 20, 2023 Current Ratio40.33 EPS Y/Y TTM81.16% Oper. Margin- RSI (14)37.27 Volatility8.04% 7.10%
Employees52 Debt/Eq0.00 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price57.29
Option/ShortYes / Yes LT Debt/Eq0.00 EPS Q/Q52.31% Payout- Rel Volume0.71 Prev Close22.52
Sales Surprise- EPS Surprise4.54% Sales Q/Q- EarningsNov 07 BMO Avg Volume234.31K Price21.81
SMA20-10.45% SMA50-16.26% SMA2003.90% Trades Volume166,921 Change-3.15%
Date Action Analyst Rating Change Price Target Change
Dec-06-24Initiated BMO Capital Markets Outperform $50
Nov-11-24Reiterated H.C. Wainwright Buy $48 → $49
Dec-15-23Initiated Jefferies Buy $41
Dec-04-23Resumed H.C. Wainwright Buy $48
Nov-17-23Initiated Truist Buy $43
Oct-31-23Initiated Guggenheim Buy $50
Oct-25-23Initiated Piper Sandler Overweight $65
Oct-20-22Initiated H.C. Wainwright Buy $18
Jul-05-22Downgrade Morgan Stanley Overweight → Equal-Weight $20 → $8
Dec-10-24 08:30AM
Nov-14-24 07:30AM
Nov-12-24 11:00PM
Nov-07-24 07:30AM
Oct-31-24 07:30AM
07:30AM Loading…
Oct-15-24 07:30AM
Oct-11-24 07:30AM
Oct-08-24 07:30AM
Sep-03-24 07:45AM
Aug-08-24 07:30AM
Aug-02-24 04:30PM
Jun-27-24 08:05AM
Jun-13-24 09:00AM
May-23-24 07:10AM
May-16-24 07:00AM
01:54PM Loading…
May-13-24 01:54PM
07:00AM
Apr-02-24 07:00AM
Mar-19-24 02:52PM
07:00AM
Mar-15-24 08:50AM
Feb-28-24 08:50AM
Feb-27-24 07:30AM
Feb-08-24 08:50AM
Feb-01-24 08:00AM
Jan-29-24 04:01PM
Jan-25-24 07:00AM
Jan-24-24 04:05PM
Jan-08-24 07:00AM
Dec-15-23 04:00PM
07:30AM Loading…
Dec-14-23 07:30AM
Nov-01-23 08:00AM
Oct-26-23 09:02PM
Oct-19-23 05:37PM
Oct-17-23 05:47PM
Oct-06-23 05:09PM
Oct-04-23 08:30AM
Jun-22-23 07:30AM
May-26-23 07:00AM
May-20-23 08:18AM
Feb-16-23 03:10PM
07:00AM
Dec-25-22 09:25AM
Nov-22-22 07:00AM
Nov-10-22 07:00AM
Nov-07-22 07:00AM
Oct-21-22 11:28AM
Oct-20-22 02:27PM
10:26AM
08:24AM
07:00AM
Oct-17-22 07:00AM
Oct-04-22 07:00AM
Sep-21-22 07:00AM
Sep-06-22 07:00AM
Aug-15-22 07:00AM
Jul-18-22 09:47AM
Jun-30-22 07:00AM
Jun-07-22 04:01PM
Jun-01-22 07:00AM
May-31-22 07:00AM
May-17-22 04:01PM
07:00AM
May-12-22 04:01PM
May-02-22 07:00AM
Apr-28-22 11:45AM
Apr-06-22 04:01PM
Mar-22-22 04:01PM
Mar-17-22 04:01PM
Feb-11-22 07:00AM
Feb-08-22 01:32PM
Jan-31-22 09:38AM
Jan-06-22 07:00AM
Jan-04-22 07:00AM
Dec-20-21 07:00AM
Dec-14-21 07:00AM
Nov-30-21 07:00AM
Nov-12-21 07:00AM
Nov-08-21 07:00AM
Nov-04-21 06:00AM
Oct-29-21 07:00AM
Oct-28-21 04:36PM
Sep-02-21 07:00AM
Aug-12-21 07:00AM
Aug-10-21 08:10AM
Jun-14-21 04:01PM
Jun-03-21 07:00AM
May-11-21 04:01PM
May-06-21 09:53PM
Tourmaline Bio, Inc. is a late-stage clinical biotechnology company, which engages in the development of medicines for patients with life-altering immune diseases. It offers the TOUR006. The company was founded by Sandeep Kulkarni on September 17, 2021 and is headquartered in New York, NY.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kulkarni Sandeep ChidambarCEOAug 21 '24Buy14.851,77926,4187,000Aug 22 04:22 PM
Kulkarni Sandeep ChidambarCEOAug 16 '24Buy13.795,22171,9985,221Aug 20 06:09 PM
MCDADE MARKDirectorJan 29 '24Buy32.50100,0003,250,000448,431Jan 31 04:26 PM